Regulation of Inflammatory Genes in Psoriasis
University of Alabama at Birmingham · NCT03125655
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 19–99 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 13
- US sites recruiting
- 1
- Study start
- April 22, 2014
- Record last updated
- April 6, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.
Being studied: Inflammatory markers
Conditions: Psoriasis; Inflammation
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Clinical diagnosis of psoriasis
- Must be age 19 or older.
- Must be Fitzpatrick skin type I, II, III, IV, V, VI.
Exclusion Criteria
- Subjects who do not have photosensitive disease and are not on photosensitizing medications.
- Subjects with a history of keloids (who are more likely to develop hypertrophic scars following skin biopsy).
- Subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants.
- Subjects who are pregnant.
Recruiting US locations
The Kirklin Clinic
Birmingham, AL 35294
Site contact: Wendy Cantrell · 205 502 9960 · wcantrell@uabmc.edu
Similar studies in Alabama
All dermatology studies in Alabama →- RecruitingHealthy volunteersPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Regeneron Pharmaceuticals
- Location
- Birmingham, AL + 5 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
Phase 2/3 Efficacy and Safety of PP405 in Adult Males
Pelage Pharmaceuticals, Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 18–55 · Men only
- RecruitingPhase 3
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Pfizer
- Location
- Birmingham, AL + 28 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Pfizer
- Location
- Birmingham, AL + 6 other US sites
- Eligibility basics
- Ages 2–11